Sodium phenylacetate
As of the edition of 20 October 2026, Sodium phenylacetate is a small molecule: marketed, first approved in 1987 (US); no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1987
- Kind
- Small molecule
- Brand name
- Ucephan
- First approved
- 23 December 1987 (US)
- Approvals on record
- 3 in 1 region
- Holder of the most recent approval
- Maia Pharmaceuticals; 3 holders in all
- Registered trials
- 2, 1 stopped early
- Disease areas
- Nervous system; Nutrition and metabolism; Blood and lymph; Cancer; Digestive system; Immune system
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 2 | 1 | 0 | 1 |
| All trials | 2 |